Plain-English translation of NCT07337421 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a treatment called mFOLFOX given as a special infusion directly into the artery that feeds the liver after you've had surgery to remove hepatocellular carcinoma (liver cancer). The goal is to see whether this medication, delivered this way, can help prevent cancer from coming back in patients who have risk factors that make recurrence more likely.
After surgery to remove liver cancer, the disease comes back in many patients, especially those with certain high-risk features like large tumors or cancer cells found in blood vessels. This trial is testing whether the medication can reduce that risk of recurrence.
You likely qualify if…
You likely don't qualify if…
You would receive up to two chemotherapy infusions through a catheter placed in the artery that feeds your liver, starting 4–8 weeks after your surgery, with a second infusion about 3 weeks later if your doctor thinks it's safe. You would then have follow-up visits every 8–12 weeks for a year, which include blood tests, imaging scans (CT or MRI), heart monitoring, and visits to check how you're doing and whether the cancer has come back.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China